期刊
CLINICAL MICROBIOLOGY AND INFECTION
卷 20, 期 6, 页码 O397-O405出版社
ELSEVIER SCI LTD
DOI: 10.1111/1469-0691.12419
关键词
Antibody level; hepatitis E virus; immunity; infection; vaccine
资金
- National High-tech R&D Program (863 Programme) [2012AA02A408]
- National Major Scientific and Technological Special Project for 'Prevention and Control of important infectious diseases' [2012ZX10002001, 2011ZX10004-903]
- National Major Scientific and Technological Special Project for 'Significant New Drugs Development' [2013ZX09101017]
- Fujian Provincial Science Fund for Distinguished Young Scholars [2011J06015]
- Jiangsu Science and Technology Support plan [BE2013723]
- Xiamen Innovax Biotech Company, Ltd.
Immunity acquired from infection or vaccination protects humans from symptomatic hepatitis E. However, whether the risk of hepatitis E virus (HEV) infection is reduced by the immunity remains unknown. To understand this issue, a cohort with 12 409 participants randomized to receive the hepatitis E vaccine Hecolin (R) or placebo were serologically followed up for 2 years after vaccination. About half (47%) of participants were initially seropositive. A total of 139 infection episodes, evidenced by four-fold or greater rise of anti-HEV level or positive seroconversion, occurred in participants who received three doses of treatment. Risk of infection was highest among the baseline seronegative placebo group participants (2.04%). Pre-existing immunity and vaccine-induced immunity lower the risk significantly, to 0.52% and 0.30%, respectively. In conclusion, both vaccine-induced and naturally acquired immunity can effectively protect against HEV infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据